The prospect of a pill rather than an injection is obviously appealing to some people, but will fear of needles be enough to ...

As we have seen in LEADER, SUSTAIN 6 and PIONEER 6 with liraglutide and semaglutide, cardiovascular benefits are also being established and this is now reflected in recent international diabetes ...

SIGNIFICANT EVENTS DURING 1 JANUARY - 31 MARCH 2025Iconovo and Lonza have entered a collaboration to develop spray-dried formulations of an intranasal biologic drug for Iconovo's proprietary intranasa ...

The big question for Lilly is whether the data are strong enough to fend off the challenge from Novo Nordisk’s once-weekly GLP-1 agonist Ozempic (semaglutide), and its recently approved once ...

An estimated 24,499 people visited the ED for adverse events related to semaglutide in the 2 years after its approval for ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

The injectable forms of semaglutide — Ozempic for diabetes and Wegovy for weight loss — have solid evidence backing up their claims of cardiovascular protection. The oral form, marketed as ...

A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...